^
Association details:
| Biomarker: | LDLR-ROS1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion
Published date:
04/20/2023
Excerpt:
Here, a 77-year-old woman was diagnosed with stage IVA lung adenocarcinoma harboring a novel low-density lipoprotein receptor (LDLR)-ROS1 fusion variant….This patient benefited from subsequent crizotinib therapy and achieved progression-free survival of 15 months without significant toxic symptoms.
DOI:
10.3389/fonc.2023.1169876
Source:
Title:
Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
Published date:
03/01/2022
Excerpt:
A 72-year-old Chinese male patient was admitted...the disease was diagnosed as a stage IIIA lung adenocarcinoma with hilar node metastasis...A novel LDLR (Exon1–14)–ROS1 (Exon34–43) fusion variant (44.8% abundance) was detected and confirmed by immunohistochemistry (IHC) staining...Crizotinib (250 mg orally twice daily) was immediately administered beginning in June 2019. Follow-up examinations were performed every 6 months after surgery, clinical and radiological follow-up showed no evidence of progression or recurrence, and the recurrence-free survival (RFS) had exceeded 29 months by the time of submission (December 2021)...
DOI:
https://doi.org/10.3389/fonc.2022.837219
